Illinois Tool Works Inc. vs uniQure N.V. Ordinary Shares — how do they compare? Illinois Tool Works Inc. trades at $271.34 (market cap $76.75B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.45B). The key difference: Illinois Tool Works Inc. is far larger — about 52.9× uniQure N.V. Ordinary Shares's market cap, and Illinois Tool Works Inc. pays a 2.55% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illinois Tool Works Inc. for 66 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| ITW | QURE | |
|---|---|---|
Market Cap | $76.75B | $1.45B |
Volume | 1,222,646 | 3,323,243 |
Sector | Industrials | Health |
52-Week High | $299.60 | $70.59 |
52-Week Low | $241.07 | $9.03 |
Typical Hold Time | 66 Days | 0 Days |
Enterprise Value | $85.60B | $707.46M |
Dividend Yield | 2.55% | — |
Signals from Pluang's Aura AI — not financial advice
ITW trades at $266.32, up 0.46% today, with a bearish technical signal but strong fundamentals including a 19.39% net income margin and consistent earnings beats. The stock is supported by a recent dividend raise to $1.72 and positive analyst upgrades, though it faces headwinds in automotive and foodservice segments. Cash flow trends show stable operations, with 2026 net cash flow projected at $51 million.
Outlook is mixed: valuation metrics like P/E of 24.12 are reasonable for a Dividend King with 59 years of increases, but high debt-to-asset ratio of 55.54% and bearish technicals pose risks. Upside to the $276.86 consensus price target depends on sustaining organic growth amid sector weaknesses.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →